Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR

Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update

March 7, 2019 4:05 PM EST

WALTHAM, Mass., March 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2018. In addition, the Company provided a clinical and business update. As of December 31, 2018, Syndax had $80.9 million in cash, cash equivalents and short-term investments.

"We expect the coming months to be a very exciting, milestone-rich time for Syndax as we continue to work towards our mission of realizing a future in which... More

Syndax to Present at the Cowen 39th Annual Health Care Conference

March 6, 2019 7:00 AM EST

WALTHAM, Mass., March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the Cowen 39th Annual Health... More